Keyphrases
Finland
93%
Prostate Cancer
92%
Confidence Interval
60%
Overall Survival
41%
Type 1 Diabetes Mellitus (T1DM)
41%
Type I Diabetes
41%
Tumor
40%
Lynch Syndrome
37%
Randomized Controlled Trial
35%
Colorectal Cancer
32%
Islet Autoimmunity
31%
Circulating Tumor DNA (ctDNA)
29%
Hazard Ratio
28%
Quality of Life
27%
Prostate Cancer Risk
27%
Uganda
27%
High Risk
26%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
25%
Breast Cancer
24%
Three-dimensional (3D)
22%
Cancer Cells
21%
Ovarian Cancer
21%
Prognostic Factors
21%
University Hospital
18%
Type 2 Diabetes Mellitus (T2DM)
18%
Health-related Quality of Life
18%
Human Adipose-derived Stem Cells (hADSCs)
18%
Low Birth Weight
17%
Chemotherapy
17%
Prostate
17%
Diabetes
17%
Clinical Trials
17%
Radiotherapy
16%
Palliative Care
16%
Population-based Study
16%
Odds Ratio
16%
In Cancer
15%
Prostate Cancer Screening
15%
Glioblastoma
15%
Lipid Supplementation
15%
Inflammation
15%
Older children
15%
Castration-resistant Prostate Cancer
14%
Single Center
14%
Enzalutamide
14%
Adjuvant Therapy
14%
Population-based
14%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
14%
Metastatic Colorectal Cancer (mCRC)
14%
Severe Malnutrition
14%
Celiac Disease
14%
Older Adults
14%
Tampere
14%
Androgen Deprivation Therapy
14%
Acute Lymphoblastic Leukemia
13%
Pulmonary Metastasis
13%
Transient Receptor Potential Vanilloid 1 (TRPV1)
13%
ENGOT
13%
Androgen Receptor
13%
Physical Activity
13%
Programmed Death-ligand 1 (PD-L1)
13%
Ready-to-use Therapeutic Food
12%
Retrospective Cohort Study
12%
Progression-free Survival
12%
Prospective Cohort Study
12%
Meta-analysis
12%
DNA Methylation (DNAm)
12%
Cancer Evolution
12%
Urinary Incontinence
12%
Randomized Trial
12%
Prostate Cancer Progression
11%
Breast Cancer Patients
11%
Bioactive Glass
11%
Malawi
11%
Mitogen-activated Protein Kinase
11%
Mismatch Repair
11%
Early Breast Cancer
11%
Randomized Placebo-controlled Trial
11%
Etiology
11%
Gene Expression
11%
Sweden
11%
Autoantibodies
11%
Stunted children
11%
Atorvastatin
11%
High-risk Human Papillomavirus (HR-HPV)
11%
Methyl
11%
Depressive Symptoms
11%
Prognostic Role
11%
Antenatal Intervention
10%
Small-for-gestational Age
10%
Metastasis
10%
Drug Response
10%
Prostate Cancer Patients
10%
High-grade Serous Ovarian Cancer (HGSOC)
10%
Environmental Determinants
10%
Prostate Cancer Cells
10%
Myopathy
10%
Cell-to-cell
10%
Body Mass Index
10%
Prognostic Value
10%
Medicine and Dentistry
Prostate Cancer
100%
Neoplasm
71%
Malignant Neoplasm
61%
Overall Survival
43%
Colorectal Carcinoma
43%
Arm
43%
Diseases
39%
Ovarian Cancer
37%
Randomized Controlled Trial
35%
Breast Cancer
34%
Quality of Life
25%
Systematic Review
25%
Cancer
24%
Immunity
23%
Biological Marker
23%
Prognostic Factor
22%
Retrospective Cohort Study
22%
Cohort Analysis
22%
Prostatectomy
22%
Radiation Therapy
22%
Circulating Tumor DNA
21%
Symptomatic Treatment
21%
Neonatal Infant
21%
Acute Lymphoblastic Leukemia
20%
Insulin Dependent Diabetes Mellitus
20%
Health Care Cost
19%
Cancer Therapy
18%
Oncology
17%
Hazard Ratio
17%
Hereditary Nonpolyposis Colorectal Cancer
17%
Autoimmunity
17%
Cancer Cell
17%
In Vitro
16%
Pediatrics
15%
Prevalence
15%
Metastatic Carcinoma
15%
Maturity Onset Diabetes of the Young
15%
Meta-Analysis
15%
Castration Resistant Prostate Cancer
15%
Adipose Tissue
14%
Cancer Mortality
14%
Immunocompetent Cell
14%
Progression Free Survival
14%
Stem Cell
14%
Metastatic Colorectal Cancer
13%
Surgery
13%
Wart Virus
13%
Lung Metastasis
13%
Clear Cell Renal Cell Carcinoma
13%
Odds Ratio
13%
Primary Tumor
13%
Low Birth Weight
12%
Tissue Regeneration
12%
Subgroup Analysis
12%
Diabetes
12%
Immunotherapy
12%
Physical Activity
12%
Clinical Trial
11%
Androgen Receptor
11%
DNA Mismatch Repair
11%
Drug Response
11%
Placebo
11%
PARP Inhibitor
11%
Decision Making
11%
Blood Pressure
11%
Magnetic Resonance Imaging
11%
Diagnosis
10%
Prostate Specific Antigen
10%
Cancer Screening
10%
Gene Expression
10%
Krukenberg Tumor
10%
Stroma
10%
Dysplasia
10%
Epithelial Cell
10%
Hip Fracture
10%
Personalized Medicine
10%
Leukemia
10%
Urinary System
10%
Observational Study
10%
Urine Incontinence
9%
Enuresis
9%
Uterine Cancer
9%
CD8 Antigen
9%
Lipid Metabolism
9%
Prospective Cohort Study
9%
Adjuvant Therapy
9%
Low and Middle Income Countries
9%
Cancer Growth
9%
Androgen Deprivation Therapy
9%
Small for Gestational Age
9%
Proportional Hazards Model
9%
Recurrent Disease
9%
Induced Pluripotent Stem Cell
8%
Minimal Residual Disease
8%
Pulse Wave Velocity
8%
Computer Assisted Tomography
8%
Ganglioglioma
8%
Infection
8%
Enzalutamide
8%
Macrophage
8%